Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3CNS 3Sarcoma 2Genitourinary 2Myeloid 1

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × tandutinib × Sarcoma × Clear all
NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡